✦ LIBER ✦

Adriamycin, vincristine and mitomycin C as first and second line therapy for advanced breast carcinoma

✍ Scribed by M. Harding; G. Sangster; R. A. V. Milsted; S. B. Kaye; K. C. Calman

Book ID: 112963004
Publisher: Springer US
Year: 1988
Tongue: English
Weight: 299 KB
Volume: 5
Category: Article
ISSN: 1357-0560
DOI: 10.1007/bf02985450

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adriamycin, vinblastine and mitomycin C

Adriamycin, vinblastine and mitomycin C as second-line chemotherapy in advanced breast cancer

✍ Aaron Sulkes; Eliahu Gez; M. Raphael Pfeffer; Raphael Catane; Rut Isacson; Shosh 📂 Article 📅 1986 🏛 Springer 🌐 English ⚖ 643 KB

A combination therapy with mitomycin-C,

A combination therapy with mitomycin-C, etoposide, doxifluridine and medroxyprogesterone acetate as second-line therapy for advanced breast cancer

✍ A. Osaki; Y. Ohi; T. Hirai; T. Toge 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 171 KB

A phase II trial of mitomycin C and 5-fl

A phase II trial of mitomycin C and 5-fluorouracil as second-line therapy in advanced breast cancer

✍ Mary E R O'Brien; E J Bayliss; Moira E Stewart; John F Smyth; Alan Rodger; R C F 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 195 KB

A combination therapy with mitomycin c,

A combination therapy with mitomycin c, etoposide, doxifluridine and medroxyprogesterone acetate as second line therapy for advanced breast cancer refractory to combination chemotherapy of cyclophosphamide, doxorubicin and 5 fluorouracil

✍ Katsumasa Kuroi; Akihiko Osaki; Hiroyuki Kawami; Shigeru Murakami; Tetsuya Toge 📂 Article 📅 1997 🏛 Springer Japan 🌐 English ⚖ 374 KB

Anastrozole is superior to tamoxifen as

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor–positive advanced breast carcinoma

✍ Stefan Gluck 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 45 KB

## Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor-Positive Advanced Breast Carcinoma I was surprised to read the recent article by Bonneterre et al. 1 The data presented in that article are the result of a retrospective analysis of a selected number of patients from

91 INVITED Update CTLA-4 Blockade Using

91 INVITED Update CTLA-4 Blockade Using Ipilimumab as First Line and Second Line Therapy for Advanced Melanoma

✍ J.D. Wolchok 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 54 KB